Literature DB >> 7478272

Anticonvulsant properties of D-20443 in genetically epilepsy-prone rats: prediction of clinical response.

J W Dailey1, J H Cheong, K H Ko, L E Adams-Curtis, P C Jobe.   

Abstract

D-20443 is an experimental antiepileptic drug. Its mechanism of antiepileptic action is unknown. We evaluated the anticonvulsant effectiveness of D-20443 against sound-induced seizures in genetically epilepsy-prone rats (GEPRs). This compound produced anticonvulsant effects against sound-induced seizures in moderate seizure GEPRs (GEPR-3s) at significantly lower doses than in severe seizure GEPRs (GEPR-9s). Based on these data and on the responses of GEPRs to other antiepileptic drugs, we predict that D-20443 will be a broad spectrum antiepileptic agent in humans. That is, we predict that D-20443 will suppress both tonic/clonic and absence seizures in humans.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7478272     DOI： 10.1016/0304-3940(95)11783-s

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN： 0304-3940            Impact factor:   3.046


  18 in total

Review 1.  Future prospects for the drug treatment of epilepsy.

Authors:  A Nicolson; J P Leach
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 2.  Controlling potassium channel activities: Interplay between the membrane and intracellular factors.

Authors:  B A Yi; D L Minor; Y F Lin; Y N Jan; L Y Jan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

Review 3.  Retigabine (ezogabine): in partial-onset seizures in adults with epilepsy.

Authors:  Emma D Deeks
Journal:  CNS Drugs       Date:  2011-10-01       Impact factor: 5.749

4.  Kv7/KCNQ/M-channels in rat glutamatergic hippocampal axons and their role in regulation of excitability and transmitter release.

Authors:  K Vervaeke; N Gu; C Agdestein; H Hu; J F Storm
Journal:  J Physiol       Date:  2006-07-13       Impact factor: 5.182

5.  Polarized axonal surface expression of neuronal KCNQ channels is mediated by multiple signals in the KCNQ2 and KCNQ3 C-terminal domains.

Authors:  Hee Jung Chung; Yuh Nung Jan; Lily Y Jan
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-30       Impact factor: 11.205

6.  Effects of retigabine on the neurodegeneration and extracellular glutamate changes induced by 4-aminopyridine in rat hippocampus in vivo.

Authors:  Gabriela Mora; Ricardo Tapia
Journal:  Neurochem Res       Date:  2005-12       Impact factor: 3.996

7.  Retigabine: in partial seizures.

Authors:  Greg L Plosker; Lesley J Scott
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

8.  Vasorelaxant effects of novel Kv 7.4 channel enhancers ML213 and NS15370.

Authors:  T A Jepps; B H Bentzen; J B Stott; O V Povstyan; K Sivaloganathan; W Dalby-Brown; I A Greenwood
Journal:  Br J Pharmacol       Date:  2014-08-14       Impact factor: 8.739

Review 9.  The new generation of GABA enhancers. Potential in the treatment of epilepsy.

Authors:  S J Czuczwar; P N Patsalos
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 10.  One man's side effect is another man's therapeutic opportunity: targeting Kv7 channels in smooth muscle disorders.

Authors:  T A Jepps; S P Olesen; I A Greenwood
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.